EP3656854 - VIRUS FOR TREATING TUMORS [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 08.03.2024 Database last updated on 03.09.2024 | |
Former | Request for examination was made Status updated on 24.04.2020 | ||
Former | The international publication has been made Status updated on 26.01.2019 | Most recent event Tooltip | 31.07.2024 | New entry: Renewal fee paid | Applicant(s) | For all designated states Xiamen University No. 422, Siming Nan Road Siming District Xiamen, Fujian 361005 / CN | For all designated states Yang Sheng Tang Company, Ltd. Room 205, No.17 Lundu Road Shuangpu Town, Xihu District, Hangzhou Zhejiang / CN | [2020/22] | Inventor(s) | 01 /
CHENG, Tong No.422 Si Ming Nan Road Siming District Xiamen Fujian 361005 / CN | 02 /
WANG, Wei No.422 Si Ming Nan Road Siming District Xiamen Fujian 361005 / CN | 03 /
WAN, Junkai No.422 Si Ming Nan Road Siming District Xiamen Fujian 361005 / CN | 04 /
FU, Wenkun No.422 Si Ming Nan Road Siming District Xiamen Fujian 361005 / CN | 05 /
YE, Xiangzhong No. 31 Kexueyuan Road Changping District Beijing 102206 / CN | 06 /
ZHANG, Jun No.422 Si Ming Nan Road Siming District Xiamen Fujian 361005 / CN | 07 /
XIA, Ningshao No.422 Si Ming Nan Road Siming District Xiamen Fujian 361005 / CN | [2020/22] | Representative(s) | Meissner Bolte Partnerschaft mbB Patentanwälte Rechtsanwälte Postfach 86 06 24 81633 München / DE | [N/P] |
Former [2020/22] | Held, Stephan Meissner Bolte Patentanwälte Rechtsanwälte Partnerschaft mbB Postfach 86 06 24 81633 München / DE | Application number, filing date | 18835927.7 | 18.07.2018 | [2020/22] | WO2018CN96100 | Priority number, date | CN201710600732 | 21.07.2017 Original published format: CN201710600732 | [2020/22] | Filing language | ZH | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2019015601 | Date: | 24.01.2019 | Language: | ZH | [2019/04] | Type: | A1 Application with search report | No.: | EP3656854 | Date: | 27.05.2020 | Language: | EN | [2020/22] | Search report(s) | International search report - published on: | CN | 24.01.2019 | (Supplementary) European search report - dispatched on: | EP | 29.03.2021 | Classification | IPC: | C12N7/00, C12N15/11, A61K35/76, A61P35/00, A61K35/768 | [2021/17] | CPC: |
A61K35/768 (EP,US);
C12N7/00 (EP,CN,KR,US);
A61K35/765 (CN,KR);
A61K35/76 (KR);
A61K48/00 (EP,KR,US);
A61K48/005 (CN,KR);
A61P35/00 (EP,KR,US);
C12N15/11 (EP,KR);
C12N15/86 (US);
C07K14/535 (US);
C07K16/2818 (US);
C07K2317/622 (US);
C12N15/113 (US);
C12N2310/141 (US);
C12N2770/32321 (EP,CN,US);
C12N2770/32332 (EP,US);
C12N2770/32333 (KR);
C12N2770/32343 (US);
|
Former IPC [2020/22] | C12N7/00, C12N15/11, A61K35/76, A61P35/00 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2020/22] | Title | German: | VIRUS ZUR BEHANDLUNG VON TUMOREN | [2020/22] | English: | VIRUS FOR TREATING TUMORS | [2020/22] | French: | VIRUS DE TRAITEMENT DE TUMEURS | [2020/22] | Entry into regional phase | 13.02.2020 | Translation filed | 13.02.2020 | National basic fee paid | 13.02.2020 | Search fee paid | 13.02.2020 | Designation fee(s) paid | 13.02.2020 | Examination fee paid | Examination procedure | 13.02.2020 | Examination requested [2020/22] | 19.10.2021 | Amendment by applicant (claims and/or description) | 13.03.2024 | Despatch of a communication from the examining division (Time limit: M04) | 12.07.2024 | Reply to a communication from the examining division | Fees paid | Renewal fee | 13.02.2020 | Renewal fee patent year 03 | 30.07.2021 | Renewal fee patent year 04 | 29.07.2022 | Renewal fee patent year 05 | 27.07.2023 | Renewal fee patent year 06 | 31.07.2024 | Renewal fee patent year 07 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [Y]WO2015007788 (SIA LATIMA [LV]) [Y] 1-14 * abstract *; | [Y]WO2016044656 (ANSUN BIOPHARMA INC [US]) [Y] 1-14 * abstract * * example 4; table 2 *; | [X]US2016312314 (STORCH GREGORY A [US], et al) [X] 10,13-15 * abstract *; | [X] - Zhang Tie Gang ET AL, "The Genomic Characterization of Enterovirus D68 from 2011 to 2015 in Beijing, China", Biomedical and environmental sciences, Netherlands, doi:10.3967/bes2016.089, (20160901), pages 675 - 677, URL: https://pubmed.ncbi.nlm.nih.gov/27806749/, (20210315), XP055785724 [X] 10,14,15 * abstract * * page 677, paragraph 2; table 1 * DOI: http://dx.doi.org/10.3967/bes2016.089 | [Y] - CHUMAKOV P M ET AL, "Oncolytic enteroviruses", MOLECULAR BIOLOGY, KLUWER ACADEMIC PUBLISHERS-PLENUM PUBLISHERS, NE, (20121009), vol. 46, no. 5, doi:10.1134/S0026893312050032, ISSN 1608-3245, pages 639 - 650, XP035122625 [Y] 1-14 * abstract * * page 641, column 2, paragraph 2 - paragraph 4 * * page 644, column 2, paragraph 4 * DOI: http://dx.doi.org/10.1134/S0026893312050032 | [A] - EMILY JANE BEK ET AL, "The Pathogenesis and Prevention of Encephalitis due to Human Enterovirus 71", CURRENT INFECTIOUS DISEASE REPORTS, CURRENT SCIENCE INC, NEW YORK, (20120526), vol. 14, no. 4, doi:10.1007/S11908-012-0267-3, ISSN 1534-3146, pages 397 - 407, XP035079523 [A] 1-14 * abstract * * page 403, column 1, paragraph 4 * DOI: http://dx.doi.org/10.1007/s11908-012-0267-3 | [A] - HUANG YUAN-PIN ET AL, "Molecular and epidemiological study of enterovirus D68 in Taiwan", JOURNAL OF MICROBIOLOGY, IMMUNOLOGY AND INFECTION, ELSEVIER, AMSTERDAM, NL, (20150918), vol. 50, no. 4, doi:10.1016/J.JMII.2015.07.015, ISSN 1684-1182, pages 411 - 417, XP085167237 [A] 1-14 * abstract * DOI: http://dx.doi.org/10.1016/j.jmii.2015.07.015 | International search | [Y]CN105518128 (SIA LATIMA) [Y] 1-11, 14 (all in part) * see abstract, and claims 1-14 *; | [A]US2016355897 (NIX WILLIAM ALLAN [US], et al) [A] 1-12, 14 (all in part)* see entire document *; | [XY] - GenBank, (20141201), Database accession no. KM851225, XP055567901 [X] 12 (in part) * ), see sequence and related information thereof), see sequence and related information thereof * [Y] 1-11, 14 (all in part) | by applicant | WO2008103755 | US2016143969 | - DOBRIKOVA et al., Mol Ther, (20080000), vol. 16, no. 11, pages 1865 - 1872 | - AU et al., Virol J, (20110000), vol. 8, page 22 | - SHAFREN et al., Int J Cancer, (20050000), vol. 115, no. 2, pages 320 - 328 | - HALEY et al., J Mol Med (Berl, (20090000), vol. 87, no. 4, pages 385 - 399 | - SCHIEBLE et al., Am J Epidemiol, (19670000), vol. 85, no. 2, pages 297 - 310 | - MERRILLGROMEIER, J Virol, (20060000), vol. 80, no. 14, pages 6936 - 6942 | - NEPLIOUEVA et al., PLoS One, (20100000), vol. 5, no. 7, page e11710 | - DOBRIKOV et al., Mol Cell Biol, (20110000), vol. 31, no. 14, pages 2947 - 2959 | - DOBRIKOV et al., Mol Cell Biol, (20130000), vol. 33, no. 5, pages 937 - 946 | - BAOHONG ZHANG et al., Developmental Biology, (20070201), vol. 302, no. 1, pages 1 - 12 | - HOU WHYANG LSLI SX et al., Virus Res, (20150000), vol. 210, pages 165 - 168 | - YIN H et al., Nat Rev Genet., (20140800), vol. 15, no. 8, pages 541 - 55 | - RILEY MKVERMERRIS W, Nanomaterials (Basel, (20170428), vol. 7, no. 5, page E94 | - "GenBank", Database accession no. X02316.1 | - RUIZ AJRUSSELL S J., MicroRNAs and oncolytic viruses. [J]. Curr Opin Virol, (20150000), vol. 13, pages 40 - 48 | - ARDOLINO MHSU JRAULET D H, "Cytokine treatment in cancer immunotherapy [J", Oncotarget, (20150000), vol. 6, no. 23, pages 19346 - 19347 | - CANDOLFI MKING GDMUHAMMAD AG et al., "Evaluation of proapototic transgenes to use in combination with Flt3L in an immune-stimulatory gene therapy approach for Glioblastoma multiforme (GBM) [J", FASEB J, (20080000), vol. 22 | - NOLAN ESAVAS PPOLICHENI AN et al., "Combined immune checkpoint blockade as a therapeutic strategy for BRCAl-mutated breast cancer [J", Science Trans Med, (20170000), vol. 9, page eaal 4922 | - ROSCA EVKOSKIMAKI JERIVERA CG et al., "Anti-angiogenic peptides for cancer therapeutics [J", Curr Pharm Biotechnol, (20110000), vol. 12, no. 8, pages 1101 - 1116 | - BIRD et al., Science, (19880000), vol. 242, pages 423 - 426 | - HUSTON et al., Proc. Natl. Acad. Sci. USA, (19880000), vol. 85, pages 5879 - 5883 | - PLUCKTHUNROSEBURGMOORE, The Pharmacology of Monoclonal Antibodies, Springer-Verlag, (19940000), vol. 113, pages 269 - 315 | - NEEDLEMAN et al., J. Mol. Biol., (19700000), vol. 48, pages 444 - 453 | - E. MEYERSW. MILLER, Comput. Appl. Biosci., (19880000), vol. 4, pages 11 - 17 | - PIRALLA et al., J Clin Microbiol, (20150000), vol. 53, no. 5, pages 1725 - 1726 | - YANG et al., Clin Vaccine Immunol, (20140000), vol. 21, no. 3, pages 312 - 320 | - HOU et al., J Virol Methods, (20150000), vol. 215-216, pages 56 - 60 | - HADAC E MKELLY E JRUSSELL S J, Mol Ther, (20110000), vol. 19, no. 6, pages 1041 - 1047 |